Details of the Drug

General Information of Drug (ID: DMSRCIS)

Drug Name

AMG 133

Indication

Disease Entry	ICD 11	Status	REF
Obesity	5B81	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody peptide conjugate

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastric inhibitory polypeptide receptor (GIPR)	TTYMKBE	GIPR_HUMAN	Antagonist/GLP1 agonist	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Obesity

ICD Disease Classification

5B81

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Gastric inhibitory polypeptide receptor (GIPR)	DTT	GIPR	6.53E-02	-0.19	-1.27

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05669599) A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. U.S.National Institutes of Health.
2	An update on peptide-based therapies for type 2 diabetes and obesity. Peptides. 2023 Mar;161:170939.